Cost-effectiveness analysis of a state funded programme for control of severe asthma.

Programa para o Controle da Asma e da Rinite Alérgica na Bahia (ProAR), Faculdade de Medicina, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
BMC Public Health (Impact Factor: 2.08). 02/2007; 7:82. DOI: 10.1186/1471-2458-7-82
Source: PubMed

ABSTRACT Asthma is one of the most common chronic diseases and a major economical burden to families and health systems. Whereas efficacy of current therapeutical options has been clearly established, cost-effectiveness analysis of public health interventions for asthma control are scarce.
81 patients with severe asthma (12-75 years) joining a programme in a reference clinic providing free asthma medication were asked retrospectively about costs and events in the previous 12 months. During 12 months after joining the programme, information on direct and indirect costs, asthma control by lung function, symptoms and quality of life were collected. The information obtained was used to estimate cost-effectiveness of the intervention as compared to usual public health asthma management. Sensitivity analysis was conducted.
64 patients concluded the study. During the 12-months follow-up within the programme, patients had 5 fewer days of hospitalization and 68 fewer visits to emergency/non scheduled medical visits per year, on average. Asthma control scores improved by 50% and quality of life by 74%. The annual saving in public resources was US$387 per patient. Family annual income increased US$512, and family costs were reduced by US$733.
A programme for control of severe asthma in a developing country can reduce morbidity, improve quality of life and save resources from the health system and patients families.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, there are no studies of well-characterized severe asthmatics in Brazil. We aimed to study a population of severe treated asthmatics still uncontrolled to characterize them and define possible phenotypes. Descriptive cross-sectional outpatient study of severe asthmatics, evaluating functional and inflammatory markers, health-related quality of life, anxiety and depression symptoms, clinical control status, and characteristics related to atopy, age of asthma onset, induced sputum eosinophil levels, and airflow limitation. We also grouped the subgroups characteristics to identify phenotypes. The study is registered on NCT 01089322. From 128 eligible patients with severe/uncontrolled asthma, 74 fulfilled the inclusion criteria. The cohort was comprised of 85% women, frequently with a body mass index higher than 31 kg m(-2), atopy (60%), early-onset disease (50%), sputum eosinophilia (80%), comorbidities, and reduced quality of life. Nonatopics had significant higher asthma onset (19 y.a.) and twice level of induced sputum eosinophil. Late-onset patients had significantly less atopy (57%) and higher levels of induced sputum eosinophils. Non-eosinophilics had lower levels of inflammatory markers. Patients with airflow limitation had more intensive care unit admissions (56%) and 1.5 times more airway resistance. Subgroups characteristics identified a priori four well-characterized phenotypes, with 55% presenting sputum eosinophilia. Our data emphasize the high burden of disease, the persistence of inflammation and the existence of clinical possible phenotypes population sharing common features with published cohorts. Despite the necessity of further investigation into pathogenic mechanisms, this study with clinically difficult patient group may help to improve future asthma care.
    Respiratory medicine 09/2011; 106(1):47-56. · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a chronic inflammatory disorder of the airways that is characterized by recurrent symptoms associated with airflow limitation and by bronchial hyper-responsiveness. Free asthma treatment has been guaranteed in Brazil since 2003, notably after the Brazilian government decided to support drugs for the most serious forms of the disease. The asthma treatment access policy in Brazil offers a new opportunity for pharmacists to work closely with patients, and for caregivers and health care teams to promote educational activities and patient counselling about asthma. Pharmacists have an important role in the management of drug therapy within the health care team. Pharmacists should be prepared to engage with the latest concept of health care delivery proposed for Brazilian Unified Health System. These are centred on forming health care networks and strengthening multidisciplinary teams to integrate all professionals who are in charge of patient care.
    International journal of clinical pharmacy. 06/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is the most common chronic disease in children in many low- and middle-income countries. In these settings, the burden of childhood asthma is increasing and is associated with severe disease. There are a number of challenges to providing optimal management of childhood asthma in such settings. These include under-diagnosis of childhood asthma, access to care, ability of healthcare workers to manage asthma, availability and affordability of inhaled therapy, environmental control of potential triggers, education of healthcare providers and of the public, and cultural or language issues. International and national guidelines for childhood asthma have been produced, but implementation remains a real challenge. Access to and affordability of essential inhaled asthma drugs, especially low-dose inhaled corticosteroids and short-acting bronchodilators, are major challenges to effective asthma control in many countries. A low-cost spacer made from a plastic bottle is effective for use with a metered-dose inhaler, but use must be included in asthma educational initiatives. Educational programs for healthcare personnel and for the public that are culturally and language appropriate are needed for effective implementation of asthma guidelines. Socioeconomic and structural barriers to care within health services remain obstacles to achieving optimal treatment of asthma for many children.
    Paediatric Drugs 09/2012; 14(6):353-9. · 1.72 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014